[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342065-105":59,"doc-detail-342065-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tuning-immune-cold-tumor-by-suppressing-usp10b7-h4-proteolytic-axis-reinvigorates-therapeutic-efficacy-of-adcs","Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs","","Research article on improving cancer therapy by tuning immune-cold tumors and increasing antibody-drug conjugate (ADC) effectiveness. Multi-omics and experimental work identify the USP10/B7-H4 proteolytic axis as a driver of crosstalk between tumor immune activity and sacituzumab govitecan (SG) response in triple-negative breast cancer (TNBC). USP10 inhibition destabilizes B7-H4, boosts tumor immunogenicity, and enhances SG-mediated tumor killing, including in USP10high/B7-H7high-signature models, suggesting B7-H4 as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tuning-immune-cold-tumor-by-suppressing-usp10b7-h4-proteolytic-axis-reinvigorates-therapeutic-efficacy-of-adcs/342065/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tuning-immune-cold-tumor-by-suppressing-usp10b7-h4-proteolytic-axis-reinvigorates-therapeutic-efficacy-of-adcs/342065.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What tumor-immune mechanism does the study focus on?","Question",{"text":112,"@type":113},"The study focuses on the USP10/B7-H4 proteolytic axis and how it mediates the interplay between tumor immune responses and ADC efficacy in TNBC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does inhibiting USP10 affect B7-H4 and treatment response?",{"text":117,"@type":113},"Inhibition of USP10 promotes degradation of B7-H4, suppressing immunosuppression and enhancing tumor immunogenicity, which improves the therapeutic efficacy of sacituzumab govitecan (SG).",{"name":119,"@type":110,"acceptedAnswer":120},"In which TNBC context is the approach most effective?",{"text":121,"@type":113},"In preclinical TNBC models, suppression of the USP10/B7-H4 axis improves SG killing and reduces tumor growth, especially for tumors with the USP10high/B7-H7high signature.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342065,1790188678,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nTuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Eﬃcacy ofADCs  \nLidan Zeng, Yueming Zhu, Xin Cui, Junlong Chi, Amad Uddin, Zhuan Zhou, Xinxin Song, Mingji Dai, Massimo Cristofanilli, Kevin Kalinsky, and Yong Wan*  \nTuning immune-cold tumor hot has largely attracted attention to improve cancer treatment, including immunotherapy and antibody-drug conjugates (ADCs). Utilizing multiomic analyses and experimental validation, this work identiﬁes a pivotal role for the USP10/B7-H4 proteolytic axis in mediating the interplay between tumor immune responses and ADC eﬃcacy, particularly for sacituzumab govitecan (SG) in treating triple negative breast cancers (TNBCs). Mechanistically, the inhibition of autocrine motility factor receptor (AMFR)-mediated ubiquitylation of B7-H4 by the deubiquitinase USP10 leads to the stabilization of B7-H4, which suppresses tumor immune activity and reduces SG treatment eﬀectiveness. Pharmacological inhibition of USP10 promotes the degradation of B7-H4, enhancing tumor immunogenicity and consequently improving the tumor-killing eﬃcacy of SG. In preclinical TNBC models, suppression of USP10/B7-H4 proteolytic axis is eﬀective in increasing SG killing eﬃcacy and reducing tumor growth, especially for the tumors with the USP10high/B7-H7high signature. Collectively, these ﬁndings uncover a novel strategy for targeting the immunosuppressive molecule B7-H4 for cancer therapy.  \napproach accompanied by immunotherapy in treating triple-negative breast cancers (TNBCs) . [5,6] TNBCs present unique therapeutic challenges due to their lack of hormone receptors and HER2 protein, which are common targets in other breast cancer subtypes. [7] Although ADCs such as sacituzumab govitecan (SG) have beneﬁted TNBC patients, certain subsets encounter therapeutic challenges due to de novo and acquired drug resistance. [8–10] Our recent big data analyses and pathological studies with various breast cancer cohorts suggest the status of immune-cold tumors to bea potentially critical barrier aﬀecting the tumor response to ADC drug treatment. Nevertheless, mechanisms underlying the interplay between tumor immunogenicity and ADC drug response remain largely unclear. Our endeavor on multiomic analyses coupled with experimental validation has drawn attention to the USP10/B7-H4 proteolytic axis as a possible pivotal target to  \n1. Introduction  \nHow to tune immune-cold tumor hot has greatly attracted our attention to improve cancer treatment. [1–4] Emergence of antibody-drug conjugates (ADCs) shed light on a new therapeutic  \npotentiate tumor immune response and augment ADC eﬃcacyin treating immune-cold TNBCs.  \nThe cytotoxic payload of ADCs is the cornerstone in the battle against tumor cells, yet its eﬀectiveness is not solely dependent on the agents’ cytotoxicity to target tumor cells. [11] It also requires  \nL. Zeng, Y. Zhu, X. Cui, J. Chi, A. Uddin, M. Dai, Y. Wan Department of Pharmacology and Chemical Biology Emory University School of Medicine  \nAtlanta, GA 30322, USA  \nE-mail: [yong.wan@emory.edu](yong.wan@emory.edu)  \nL. Zeng, Y. Zhu, X. Cui, A. Uddin, K. Kalinsky, Y. Wan Winship Cancer Institute  \nEmory University School of Medicine Atlanta, GA 30322, USA  \nJ. Chi  \nDGP graduate program  \nNorthwestern University Feinberg School of Medicine Chicago, IL 60611, USA  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202400757](https://doi.org/10.1002/advs.202400757)[ ](https://doi.org/10.1002/advs.202400757)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202400757  \nZ. Zhou, X. Song Department of Surgery  \nUT","cbCaia4aEfHkEIBb","https://ap.wps.com/l/cbCaia4aEfHkEIBb","pdf",17234458,"English","# Introduction\n## Antibody-drug conjugates and immune-cold TNBC\n## USP10/B7-H4 proteolytic axis in tumor-immune interplay","[{\"question\":\"What tumor-immune mechanism does the study focus on?\",\"answer\":\"The study focuses on the USP10/B7-H4 proteolytic axis and how it mediates the interplay between tumor immune responses and ADC efficacy in TNBC.\"},{\"question\":\"How does inhibiting USP10 affect B7-H4 and treatment response?\",\"answer\":\"Inhibition of USP10 promotes degradation of B7-H4, suppressing immunosuppression and enhancing tumor immunogenicity, which improves the therapeutic efficacy of sacituzumab govitecan (SG).\"},{\"question\":\"In which TNBC context is the approach most effective?\",\"answer\":\"In preclinical TNBC models, suppression of the USP10/B7-H4 axis improves SG killing and reduces tumor growth, especially for tumors with the USP10high/B7-H7high signature.\"}]","Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs | PDF",1790044986,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4340a1bafdef2d7653cc03aa4bde5d07.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae7591abc28b307d78972cbf1df8716d.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a188db24151027ced0266c1b5595d87.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/397337c3f508cfd263f99b090e6daba5.webp",980,1287]